

# Eliza A Hawkes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2574767/publications.pdf>

Version: 2024-02-01

110  
papers

1,986  
citations

279701

23  
h-index

276775

41  
g-index

112  
all docs

112  
docs citations

112  
times ranked

3178  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet</i> , The, 2013, 381, 1817-1826.	6.3	450
2	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
3	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, <i>KRAS</i> Wild-Type, Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv258.	3.0	72
4	Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy?. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1019-1024.	1.9	71
5	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. <i>Annals of Oncology</i> , 2017, 28, 2511-2516.	0.6	64
6	Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2010, 9, 274-281.	1.0	63
7	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. <i>Blood</i> , 2021, 137, 1468-1477.	0.6	59
8	Programmed cell death-1 inhibition in lymphoma. <i>Lancet Oncology</i> , The, 2015, 16, e234-e245.	5.1	56
9	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , the, 2018, 5, e190-e200.	2.2	50
10	Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. <i>Blood Reviews</i> , 2018, 32, 400-415.	2.8	49
11	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia</i> , 2020, 34, 2184-2197.	3.3	45
12	Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. <i>Journal of Clinical Medicine</i> , 2018, 7, 62.	1.0	43
13	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	3.2	42
14	Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. <i>Oncologist</i> , 2012, 17, 1562-1573.	1.9	41
15	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. <i>British Journal of Haematology</i> , 2016, 175, 668-672.	1.2	38
16	Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. <i>Annals of Oncology</i> , 2017, 28, 1540-1546.	0.6	35
17	Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible. <i>Journal of Clinical Oncology</i> , 2011, 29, e560-e562.	0.8	31
18	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , 2021, 192, 1049-1053.	1.2	31

#	ARTICLE	IF	CITATIONS
19	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. <i>European Journal of Cancer</i> , 2011, 47, 1146-1151.	1.3	29
20	Pembrolizumab in relapsed or refractory Richter syndrome. <i>British Journal of Haematology</i> , 2020, 190, e117-e120.	1.2	29
21	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. <i>BMC Cancer</i> , 2012, 12, 326.	1.1	26
22	Relationship Between Colorectal Cancer Biomarkers and Response to Epidermal Growth Factor Receptor Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , 2010, 28, e529-e531.	0.8	23
23	Diagnosis and management of rare gastrointestinal lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 2341-2350.	0.6	23
24	Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. <i>British Journal of Haematology</i> , 2019, 187, 174-184.	1.2	23
25	Limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 822-834.	0.6	22
26	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 245-257.	1.0	20
27	Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab chemotherapy combinations. <i>British Journal of Haematology</i> , 2019, 187, 73-81.	1.2	19
28	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. <i>Blood</i> , 2019, 134, 2874-2874.	0.6	19
29	The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. <i>Leukemia and Lymphoma</i> , 2012, 53, 354-361.	0.6	16
30	Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. <i>Annals of Hematology</i> , 2016, 95, 809-816.	0.8	16
31	Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 111-114.	0.7	15
32	Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. <i>Blood Reviews</i> , 2017, 31, 23-35.	2.8	15
33	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. <i>Blood Advances</i> , 2019, 3, 2804-2811.	2.5	15
34	Treatment of metastatic colorectal cancer: focus on panitumumab. <i>Cancer Management and Research</i> , 2015, 7, 189.	0.9	14
35	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. <i>Oncotarget</i> , 2017, 8, 64999-65008.	0.8	14
36	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021, 138, 181-181.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Rechallenge with Platinum plus Fluoropyrimidine +/- Epirubicin in Patients with Oesophagogastric Cancer. <i>Oncology</i> , 2010, 79, 150-158.	0.9	13
38	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. <i>Leukemia and Lymphoma</i> , 2017, 58, 1805-1813.	0.6	13
39	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2012, 23, 942-947.	0.6	12
40	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 219-226.	1.1	11
41	An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2749-2751.	0.6	11
42	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018, 59, 1586-1595.	0.6	10
43	Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission. <i>British Journal of Cancer</i> , 2018, 119, 546-550.	2.9	10
44	Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study. <i>Blood</i> , 2019, 134, 1523-1523.	0.6	10
45	The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 15-24.	1.2	9
46	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study. <i>Blood</i> , 2018, 132, 2969-2969.	0.6	9
47	Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. <i>Blood</i> , 2020, 136, 43-44.	0.6	9
48	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. <i>Blood</i> , 2016, 128, 1746-1746.	0.6	9
49	Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. <i>Seminars in Radiation Oncology</i> , 2011, 21, 196-202.	1.0	8
50	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. <i>Annals of Hematology</i> , 2014, 93, 827-834.	0.8	8
51	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 13544.	1.6	8
52	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021, 192, 1015-1019.	1.2	8
53	Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years. <i>British Journal of Haematology</i> , 2021, 193, 741-749.	1.2	8
54	Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRP $\alpha$ ) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). <i>Blood</i> , 2021, 138, 2493-2493.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3215-3216.	0.8	7
56	Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study. <i>BMJ Open</i> , 2020, 10, e038312.	0.8	6
57	A consensus statement on the use of biosimilar medicines in hematology in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 211-221.	0.7	6
58	Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study. <i>Blood</i> , 2021, 138, 304-304.	0.6	6
59	Toxicity associated with high-dose intravenous methotrexate for hematological malignancies. <i>Leukemia and Lymphoma</i> , 2022, 63, 2375-2382.	0.6	6
60	Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study. <i>Supportive Care in Cancer</i> , 0, , .	1.0	6
61	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 253-260.	0.8	5
62	Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients. <i>Supportive Care in Cancer</i> , 2019, 27, 1223-1227.	1.0	5
63	Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2021, 62, 330-336.	0.6	5
64	Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2021, 107, 475-483.	1.1	5
65	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. <i>Targeted Oncology</i> , 2021, 16, 761-771.	1.7	5
66	The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial. <i>Blood</i> , 2021, 138, 45-45.	0.6	5
67	Rare Case of Precursor B-Cell Acute Lymphoblastic Leukemia Presenting As a Solitary Paraspinal Mass Alone. <i>Journal of Clinical Oncology</i> , 2013, 31, e383-e385.	0.8	4
68	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , 2017, 140, 431-439.	2.3	4
69	Limited utility of routine chest X-ray in initial evaluation of neutropenic fever in patients with haematological diseases undergoing chemotherapy. <i>Internal Medicine Journal</i> , 2018, 48, 556-560.	0.5	4
70	Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 133-140.	1.1	4
71	Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e179-e184.	0.2	4
72	Mycosis fungoides and Szary syndrome: Australian clinical practice statement. <i>Australasian Journal of Dermatology</i> , 2021, 62, e8-e18.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Flexible sigmoidoscopy "valuable in colorectal cancer. Nature Reviews Clinical Oncology, 2010, 7, 488-490.	12.5	3
74	Reply to M. Mohiuddin et al. Journal of Clinical Oncology, 2011, 29, 2737-2738.	0.8	3
75	CHOP VERSUS GEM" IN THE FIRST"LINE TREATMENT OF T"CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO" TRIAL. Hematological Oncology, 2017, 35, 75-76.	0.8	3
76	Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 2021, 38, 3789-3802.	1.3	3
77	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NRCI R-CHOP 14 v 21 Trial. Blood, 2015, 126, 2689-2689.	0.6	3
78	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. HemaSphere, 2021, 5, e648.	1.2	3
79	Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?. Lancet Oncology, The, 2010, 11, 1020-1021.	5.1	2
80	Diagnostic Medical Radiation Exposure in Surveillance of Aggressive Lymphoma: Clinical Trial Design Should Reflect Clinical Practice. Journal of Clinical Oncology, 2015, 33, 1219-1220.	0.8	2
81	Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory?. Journal of Clinical Oncology, 2017, 35, 371-372.	0.8	2
82	Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support. Journal of Clinical Oncology, 2017, 35, 4093-4094.	0.8	2
83	Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials. Oncology, 2019, 97, 270-276.	0.9	2
84	Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care. Lancet Haematology,the, 2019, 6, e119.	2.2	2
85	Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL. Journal of Clinical Oncology, 2020, 38, 4221-4222.	0.8	2
86	Can PET eradicate irradiation in PMBCL?. Blood, 2020, 136, 2725-2726.	0.6	2
87	Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 226-233.	0.7	2
88	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NRCI R-CHOP 14 Versus 21 Phase III Trial. Blood, 2018, 132, 2956-2956.	0.6	2
89	AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2019, 134, 5332-5332.	0.6	2
90	The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. Blood, 2019, 134, 3986-3986.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2014, 124, 1723-1723.	0.6	2
92	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2009, 8, 185-189.	1.0	1
93	Echocardiography has low utility in cancer patients with <i>Staphylococcus aureus</i> bacteraemia: findings from a retrospective study. <i>Supportive Care in Cancer</i> , 2018, 26, 3083-3089.	1.0	1
94	Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression. <i>JCO Oncology Practice</i> , 2020, 16, e1315-e1323.	1.4	1
95	Exploration of motivation to participate in a study of cancer-related cognitive impairment among patients with newly diagnosed aggressive lymphoma: a qualitative sub-study. <i>Supportive Care in Cancer</i> , 2022, 30, 1331-1339.	1.0	1
96	Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance. <i>Blood</i> , 2018, 132, 4148-4148.	0.6	1
97	Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 4094-4094.	0.6	1
98	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. <i>Blood</i> , 2014, 124, 1719-1719.	0.6	1
99	Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis. <i>Blood</i> , 2019, 134, 1620-1620.	0.6	1
100	Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. <i>Blood</i> , 2019, 134, 5328-5328.	0.6	1
101	Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. <i>Internal Medicine Journal</i> , 2021, , .	0.5	1
102	Metastatic breast cancer presenting as a primary hindgut neuroendocrine tumour. <i>Anticancer Research</i> , 2010, 30, 3015-8.	0.5	1
103	Inferior vena caval leiomyosarcoma in a patient with past bilateral retinoblastoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 181-183.	0.7	0
104	ASPECCT: panitumumab versus cetuximab for colorectal cancer. <i>Lancet Oncology</i> , The, 2014, 15, e302-e303.	5.1	0
105	EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV-SPECIFIC CTL AND IBRUTINIB THERAPY. <i>Hematological Oncology</i> , 2019, 37, 130-132.	0.8	0
106	Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial. <i>Blood</i> , 2015, 126, 1516-1516.	0.6	0
107	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. <i>Blood</i> , 2015, 126, 1499-1499.	0.6	0
108	Patient Selection for High-Dose Methotrexate As Central Nervous System Prophylaxis in Diffuse Large B-Cell Lymphoma in Australia: Are We Getting It Right?. <i>Blood</i> , 2016, 128, 4217-4217.	0.6	0



#	ARTICLE	IF	CITATIONS
109	An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice. <i>Blood</i> , 2019, 134, 2849-2849.	0.6	0
110	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 36-38.	0.6	0